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Abstract
We have studied transmitted drug resistance (TDR) in 1.864
antiretroviral-naı¨ve patients entering CoRIS (Spain) during
2007–2010. An overall 8.58% TDR was observed (3.92%,
nucleoside reverse transcriptase inhibitors (NRTIs); 3.86%,
non-nucleoside reverse transcriptase inhibitors (NNRTIs);
2.31%, protease inhibitors), with a signiﬁcant decreasing
trend over time for NNRTIs (5.53%, 2007; 2.45%, 2010; p
for trend = 0.044). Non-B subtype prevalence was 15.93%,
with a signiﬁcant increase (11.95%, 2007; 18.14%, 2010; p for
trend = 0.018), mainly related to immigration. Having no for-
mal education increased the risk of TDR to NNRTIs (OR,
7.26), and carrying a non-B subtype reduced the risk of TDR
to NRTIs (OR, 0.27). These ﬁndings may have important
implications for treatment guidelines and laboratory testing
recommendations.
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Introduction
CoRIS is an open, multicentre, prospective cohort of HIV-
positive, antiretroviral-naı¨ve subjects over 13 years old that
offers relevant information about the current epidemiological
proﬁle of HIV infection in Spain [1]. A previous analysis of
viral sequences in CoRIS was carried out in 2008 and has
been published elsewhere [2]. However, since a national rec-
ommendation to perform HIV resistance testing to every
patient upon HIV diagnosis [3] was issued in 2007, we
expected this period to be more representative of both
transmitted drug resistance (TDR) and non-B subtypes. In
this report we describe TDR and non-B subtypes in CoRIS
from 2007 to 2010, and we evaluate their association with
clinical and sociodemographical variables.
Resistance-associated mutations were evaluated following
the 2009 WHO surveillance list [4]. HIV subtype was ascribed
using the protease gene with the Therapy Edge (ABL, Loux-
embourg) subtyping tool. Prevalence of TDR and non-B viral
subtypes and its trend over time was assessed (chi-square
test). Multiple logistic regression was used to analyze their
association with variables at sampling dates ±2 months (CD4
count and viral load; duration of infection; CDC stage; history
of delayed diagnosis (CD4 < 350 cells/mm3); sex; age; trans-
mission category; educational level; and country of origin).
From 2007 to 2010 a FASTA sequence was obtained for
1.864 patients, with a median time from cohort entry to
resistance study of 0 days (IQR, )21–15). A description of
the study population by year is shown in Table 1. A total of
160 patients (8.58% (95% CI, 7.31–9.86)) had at least one
mutation that conferred resistance to antiretroviral drugs
(ARV). A similar prevalence was found for nucleoside reverse
transcriptase inhibitors (NRTIs) and non-nucleoside reverse
transcriptase inhibitors (NNRTIs) (3.92% (95% CI, 3.03–4.80)
and 3.86% (95% CI, 2.99–4.74), respectively). Resistance to
protease inhibitors (PIs) was less prevalent, of 2.31% (95% CI,
1.62–2.99). TDRs to two and three classes of ARV were
uncommon (1.18% (95% CI, 0.69–1.67) and 0.16% (95% CI,
)0.02–0.34), respectively), and did not change over time. As
in previous studies [5–7], T215 revertants and K103N were
the most prevalent mutations (Table 2).
A signiﬁcant decreasing trend was found for resistance to
NNRTIs, from 5.53% (95% CI, 3.42–7.65) in 2007 to 2.45%
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(95% CI, 0.94–3.96) in 2010 (p for trend = 0.044). This
explained a slight non-signiﬁcant decreasing trend for global
TDR (p for trend = 0.095), while no trend was found for
NRTIs or PIs (Fig. 1). The decrease shown in overall TDR,
together with the very low detection of TDR to more than
one ARV class may have important implications for treatment
guideline recommendations in the future [8]. As a recent
study in Ireland discusses [9], our study may support the
hypothesis that there may be no need to screen for PI resis-
tance, and that a NNRTI-only approach could be more cost-
effective, though these data need to be conﬁrmed in the light
of the low prevalence to NNRTIs found in Spain in 2010.
Regarding associated variables, there was a non-statistically
signiﬁcant higher risk of TDR to NRTIs and NNRTIs during
the recent infection phase. Having no formal education
increased the risk of resistance to NNRTIs (OR, 7.26; 95% CI,
2.60–20.22) and to NRTIs (non-stastically signiﬁcant), com-
pared with having achieved higher education. We hypothesize
two factors that could explain a higher circulation of strains
carrying mutations within low socioeconomic stratums. Edu-
cational level has been previously associated with a poorer
virological and immunological response to treatment [10],
possibly explained by worse adherence to treatment and
increased risk of secondary mutations. Also, subjects from the
pre-HAART era in Spain, who may have been exposed to
mono-therapy, were predominantly injecting drug users of
low educational level. These results point out the importance
of including socioeconomic variables in TDR studies.
TABLE 1. Baseline characteristics of the study population
2007 2008 2009 2010 Full period
p
452 506 498 408 1864
n (%) n (%) n (%) n (%) n (%)
Sex
Male 407 (90.0) 414 (81.8) 442 (88.8) 365 (89.5) 1628 (87.34) <0.01
Female 45 (10.0) 92 (18.2) 56 (11.2) 43 (10.5) 236 (12.7)
Median age (IQR)a 34.1 (28.2–41.9) 34.3 (28.6–41.1) 33.0 (27.9–39.7) 34.0 (28.3–40.2) 33.9 (28.3–40.6) 0.17
Mode of transmission
IDU 32 (7.1) 43 (8.5) 22 (4.4) 21 (5.2) 118 (6.3) <0.01
MSM 303 (67.0) 301 (59.5) 371 (74.5) 307 (75.2) 1282 (68.8)
Heterosexual 110 (24.3) 152 (30.0) 96 (19.3) 67 (16.4) 425 (22.8)
Other/NA 7 (1.6) 10 (2.0) 9 (1.8) 13 (3.2) 39 (2.1)
Country of origin
Spain 307 (67.9) 356 (70.4) 366 (73.5) 269 (65.9) 1298 (69.6) 0.29
Europe (other) 20 (4.4) 28 (5.5) 21 (4.2) 24 (5.9) 93 (5.0)
Africa 21 (4.7) 20 (4.0) 21 (4.2) 12 (2.9) 74 (4.0)
Latin America 100 (22.1) 96 (19.0) 86 (17.3) 101 (24.8) 383 (20.5)
Other/unknown 4 (0.9) 6 (1.2) 4 (0.8) 2 (0.5) 16 (0.9)
Educational level
Higher education 107 (23.7) 131 (25.9) 153 (30.7) 131 (32.1) 522 (28.0) <0.01
Secondary school 165 (36.5) 167 (33.0) 169 (33.9) 140 (24.3) 641 (34.4)
Primary school 107 (23.7) 141 (27.9) 97 (19.5) 94 (23.0) 439 (23.6)
No studies 13 (2.9) 13 (2.6) 17 (3.4) 2 (0.5) 45 (2.4)
Unknown 60 (13.3) 54 (10.7) 62 (12.5) 41 (10.1) 217 (11.6)
Viral load (log copies/mL)a
n 288 352 353 300 1293 0.38
Median (IQR) 4.6 (4.1–5.1) 4.5 (4.0–5.0) 4.6 (4.1–5.1) 4.6 (4.1–5.1) 4.6 (4.0–5.1)
CD4 count (cells/mm3)a
n 357 411 397 350 1515 0.08
Median (IQR) 375 (223–567) 363 (226–545) 394 (251–591) 398.5 (245–580) 383 (235–567)
Duration of the infectiona
Recent infection 42 (9.3) 44 (8.7) 50 (10.0) 37 (9.1) 173 (9.3) 0.72
Chronic infection 110 (24.3) 105 (20.8) 111 (22.3) 102 (25.0) 428 (23.0)
Not evaluable 300 (66.4) 357 (70.6) 337 (67.7) 269 (65.9) 1263 (67.8)
CDC stagea
A 377 (83.4) 432 (85.4) 450 (90.4) 365 (89.5) 1624 (87.1) 0.01
B 40 (8.9) 31 (6.1) 22 (4.4) 22 (5.4) 115 (6.2)
C 35 (7.7) 43 (8.5) 26 (5.2) 21 (5.2) 125 (6.7)
History of delayed diagnosis
Yes 135 (29.9) 178 (35.2) 134 (26.9) 112 (27.5) 559 (30.0) 0.05
No 229 (50.7) 240 (47.4) 271 (54.4) 230 (56.4) 970 (52.0)
Not evaluable 88 (19.5) 88 (17.4) 93 (18.7) 66 (16.2) 335 (18.0)
NA, not available; IQR, interquartile range.
aAt the time of the resistance testing; IDU, injecting drug users; MSM, men who have sex with men.
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Non-B subtypes are clearly represented in newly diag-
nosed patients in Spain; 297 subjects had a non-B subtype,
giving a prevalence of 15.93% (95% CI, 14.27–17.60). Inter-
estingly, the proportion of non-B infections increased along
the study period, from 11.95% (95% CI, 8.95–14.95) in 2007
to 18.14% (95% CI, 14.38–21.89) in 2010 (p for trend =
0.018). Circulating recombinant forms (CRFs) accounted for
two-thirds of non-Bs (61.95% (n = 184)), and constituted
9.87% of all HIV infections. The most prevalent subtypes
were CRF02_AG (4.24%; 95% CI, 3.32–5.15), subtype F1
(1.61%; 95% CI, 1.04–2.18), subtype D (1.50%; 95% CI, 0.95–
2.05), subtype G (1.07%; 95% CI, 0.60–1.54) and CRF12_BF
(1.07%; 95% CI, 0.60–1.54).
As in Western Europe [6,9,11–15], in Spain the increase
in non-Bs is related mainly to immigration, as non-B subtypes
were more common in people of non-Spanish origin. Nearly
12% of HIV-infected native Spaniards carried a non-B variant
(11.79%; 95%CI: 10.03–13.54), and prevalence was higher for
people originating from Africa (sub-Saharan (81.77%; 95% CI,
69.69–91.85) and northern (36.36%; 95% CI, 14.53–58.19)),
Eastern Europe (27.96%; 95% CI, 18.66–37.25) and Latin-
America (17.23%; 95% CI, 13.43–21.03). Subjects infected
through heterosexual sex also showed an increased risk of
non-B subtypes (OR, 1.84; 95% CI, 0.99–3.43; p = 0.053).
Patients infected by a non-B subtype were at a 73% lower
risk (OR, 0.27; 95% CI, 0.09–0.80) of having resistance to
TABLE 2. Prevalence of mutations from the WHO transmitted drug resistance surveillance list
NRTI mutations NNRTI mutations PI mutations
Mutation n (%) Mutation n (%) Mutation n (%)
M41L 21 (1.13) L100I 3 (0.16) L24I 1 (0.05)
K65R 1 (0.05) K103N/S 59 (3.17) D30N 1 (0.05)
D67EGN 17 (0.91) V106AM 0 (0.00) V32I 3 (0.16)
T69D 3 (0.16) Y181CIV 7 (0.38) M46IL 12 (0.64)
K70ER 5 (0.27) Y188CHL 3 (0.16) I47AV 3 (0.16)
L74IV 4 (0.21) G190AES 8 (0.43) I50LV 1 (0.05)
F77L 1 (0.05) P225H 1 (0.05) F53LY 4 (0.21)
Y115F 2 (0.11) I54ALMSTV 6 (0.32)
M184IV 9 (0.48) G73ACST 1 (0.05)
L210W 2 (0.11) L76V 1 (0.05)
T215REVa 25 (1.34) V82ACFLMST 6 (0.32)
T215YF 2 (0.10) N83D 1 (0.05)
K219EQNR 22 (1.18) I84ACV 0 (0.00)
TAMS 69 (3.70) I85V 2 (0.11)
N88DS 4 (0.21)
L90M 13 (0.70)
1 mut. 42 (2.25) 1 mut. 61 (3.27) 1 mut. 36 (1.93)
2 mut. 25 (1.32) 2 mut. 11 (0.59) 2 mut. 2 (0.11)
>3 mut. 6 (0.32) >3 mut. 0 (0.00) >3 mut. 5 (0.26)
Prevalence [95%CI] 73 (3.92) [3.03–4.80] Prevalence [95%CI] 72 (3.86) [2.99–4.74] Prevalence [95%CI] 43 (2.31) [1.62–2.99]
NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; TAMs, thymidine associated mutations.
Amino acid abbreviations: A, alanine; C, cysteine; D, aspartate; E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M methionine; N,




































































FIG. 1. Prevalence of TDR by antiretroviral family and non-B subtypes between 2007 and 2010. NRTI, nucleoside reverse transcriptase inhibi-
tors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease inhibitors. CRFs, circulating recombinant forms. A signiﬁcant decreas-
ing trend was found for resistance to NNRTIs (p for trend = 0.044).
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the NRTI class than those with a B subtype. In contrast to
other studies [15–17], we did not ﬁnd any differences in
TDR to NNRTIs or PIs; of note, the panel of resistance
mutations associated with TDR proposed by Bennett et al.
[4] does not include clade-speciﬁc polymorphisms, especially
in the protease, that other studies may consider as resis-
tance mutations [18].
In summary, we have described the trends in TDR and
subtype introduction in Spain in the years 2007–2010. A
decline in TDR has been documented, reaching a statistically
signiﬁcant decrease for TDR to the NNRTI class, a ﬁnding
that may inﬂuence treatment and laboratory testing recom-
mendations. Our study has also identiﬁed the association
between having TDR and low educational level, a proxy for
socio-economic status. The risk of transmission of multidrug-
resistant genotypes remains low in Spain. Finally, this study
conﬁrms a signiﬁcant increase in non-B subtype infections
from 2007 to 2010 and its association with a foreign origin.
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Appendix 1
CoRIS Resistance Group
Steering Committee: Juan Berenguer, Julia del Amo,
Federico Garcı´a, Fe´lix Gutie´rrez, Pablo Labarga, Santiago Mo-
reno y Marı´a A´ngeles Mun˜oz.
Data analysis: Paz Sobrino Vegas, Victoria Hernando Se-
bastia´n, Bele´n Alejos Ferreras, De´bora A´lvarez, Susana
Monge, Inma Jarrı´n, Santiago Pe´rez Cachafeiro.
BioBank: M A´ngeles Mun˜oz-Ferna´ndez, Isabel Garcı´a-
Merino, Coral Go´mez Rico, Jorge Gallego de la Fuente y Al-
mudena Garcı´a Torre.
Participants
Hospital Universitario de Canarias (Santa Cruz de Tenerife):
Juan Luis Go´mez Sirvent, Patricia Rodrı´guez Fortu´nez, Marı´a
Remedios Alema´n Valls, Marı´a del Mar Alonso Socas, Marı´a
Inmaculada Herna´ndez Herna´ndez, Felicitas Dı´az-Flores, Da´cil
Garcı´a Rosado y Ricardo Pelazas Gonza´lez.
Hospital Carlos III (Madrid): Vicente Soriano, Pablo
Labarga, Pablo Barreiro, Francisco Blanco, Luz Martı´n Car-
bonero, Eugenia Vispo, Carmen Solera, Carmen de Mendoza,
Ana Trevin˜o, Eva Poveda, Gustavo Manuzza, Lourdes Anta.
Hospital Clinic – IDIBAPS, Universidad de Barcelona (Bar-
celona): Jose´ M. Miro´, Christian Manzardo, Laura Zamora,
In˜aki Pe´rez, Mª Teresa Garcı´a, Carmen Ligero, Jose´ Luis
Blanco, Felipe Garcı´a-Alcaide, Esteban Martı´nez, Josep Mall-
olas, Jose´ M. Gatell.
Hospital Doce de Octubre (Madrid): Rafael Rubio, Fede-
rico Pulido, Silvana Fiorante, Jara Llenas, Violeta Rodrı´guez,
Mariano Matarranz.
Hospital Donostia (San Sebastia´n): Jose´ Antonio Iribarren,
Julio Arrizabalaga, Marı´a Jose´ Aramburu, Xabier Camino,
Francisco Rodrı´guez-Arrondo, Miguel A´ngel von Wichmann,
Lidia Pascual Tome´, Miguel A´ngel Goenaga, Mª Jesu´s Bustin-
duy, Harkaitz Azkune Galparsoro.
Hospital General Universitario de Elche (Elche): Fe´lix Gut-
ie´rrez, Mar Masia´, Sergio Padilla, Cristina Lo´pez, Juan Carlso
Rodrı´guez, Andre´s Navarro, Fernando Montolio, Catalina
Robledano Garcı´a, Rafael Pascual.
Hospital Germans Trı´as i Pujol (Badalona): Bonaventura
Clotet, Cristina Tural, Lidia Ruiz, Cristina Miranda, Roberto
Muga, Jordi Tor, Arantza Sanvisens.
Hospital Gregorio Maran˜o´n (Madrid): Juan Berenguer, Juan
Carlos Lo´pez Bernaldo de Quiro´s, Pilar Miralles, Jaime Cosı´n
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Ochaı´ta, Matilde Sa´nchez Conde, Isabel Gutie´rrez Cuellar,
Margarita Ramı´rez Schacke, Bele´n Padilla Ortega, Paloma Gi-
jo´n Vidaurreta.
Hospital Universitario La Paz (Madrid): Juan Gonza´lez Gar-
cı´a, Ignacio Bernardino de la Serna, Jose´ Ramo´n Arribas
Lo´pez, Marı´a Luisa Montes Ramı´rez, Jose Mª Pen˜a, Blanca Ar-
ribas, Juan Miguel Castro, Francisco Javier Zamora Vargas, Ig-
nacio Pe´rez Valero, Miriam Este´banez, Silvia Garcı´a
Bujalance, Natalia Stella y Jesu´s Mingorance.
Hospital de la Princesa (Madrid): Ignacio de los Santos,
Jesu´s Sanz Sanz, Ana Salas Aparicio, Cristina Sarria´ Cepeda.
Hospital San Pedro-CIBIR (Logron˜o): Jose´ Antonio Oteo,
Jose´ Ramo´n Blanco, Valvanera Ibarra, Luis Metola, Mercedes
Sanz, Laura Pe´rez-Martı´nez.
Hospital Universitario Mutua de Terrassa (Terrassa):
David Dalmau, Angels Jae´n Manzanera, Mireia Cairo´ Llobell,
Daniel Irigoyen Puig, Laura Iba´n˜ez, Queralt Jordano Mont-
an˜ez, Mariona Xercavins Valls, Javier Martinez-Lacasa, Pablo
Velli, Roser Font.
Hospital de Navarra (Pamplona): Marı´a Rivero, Itziar Casa-
do, Jorge Dı´az, Javier Uriz, Jesu´s Repa´raz, Carmen Irigoyen,
Marı´a Jesu´s Arraiza.
Hospital Parc Taulı´ (Sabadell): Ferra´n Segura, Marı´a Jose´
Amengual, Eva Penelo, Gemma Navarro, Montserrat Sala,
Manuel Cervantes, Valentı´n Pineda.
Hospital Ramo´n y Cajal (Madrid): Santiago Moreno, Jose´
Luis Casado, Fernando Dronda, Ana Moreno, Marı´a Jesu´s
Pe´rez Elı´as, Dolores Lo´pez, Carolina Gutie´rrez, Beatriz Her-
na´ndez, Marı´a Pumares, Paloma Martı´.
Hospital San Cecilio (Granada): Federico Garcı´a Garcı´a,
Jose´ Herna´ndez Quero, Alejandro Pen˜a Monje, Leopoldo
Mun˜oz Medina, Jorge Parra Ruiz, Vicente Guillot, Marta Alv-
arez y Natalia Chueca.
Centro Sanitario Sandoval (Madrid): Jorge Del Romero
Guerrero, Carmen Rodrı´guez Martı´n, Teresa Puerta Lo´pez,
Juan Carlos Carrio´ Montiel, Paloma Raposo, Mar Vera Garcı´a
y Juan Ballesteros Martı´n.
Hospital Son Espases (Palma de Mallorca): Melchor Riera,
Javier Murillas, Maria Pen˜aranda, Maria Leyes, Mª Angels Ri-
bas, Antoni Campins, Concepcion Villalonga, Carmen Vidal.
Hospital Universitario de Valme (Sevilla): Juan Antonio
Pineda, Eva Recio Sa´nchez, Fernando Lozano de Leo´n, Juan
Macı´as, Jose´ Carlos Palomares, Manuel Parra, Jesu´s Go´mez-
Mateos.
Hospital Virgen de la Victoria (Ma´laga): Jesu´s Santos Gon-
za´lez, Manuel Ma´rquez Solero, Isabel Viciana Ramos, Rosario
Palacios Mun˜oz.
Hospital Universitario Virgen del Rocı´o (Sevilla): Pompeyo
Viciana, Manuel Leal, Luis Fernando Lo´pez-Corte´s, Mo´nica
Trastoy, Pilar Pe´rez Romero.
Centro Colaborador: Centro Nacional de Microbiologı´a
(Majadahonda): Lucı´a Pe´rez A´lvarez, Miguel Thomson Oka-
tsu, Elena Delgado Blanco, Yolanda Vega Rocha.
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